5 withdrawn. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Withdrawn 5 |
| Phase 1 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Glaucoma: new trials by email Literature Review of Glaucoma trials Research Report on Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) Everolimus - Sturge Weber Syndrome | Phase 2 | Withdrawn | Baylor College of Medicine | 2014-04-01 | 2016-05-05 | |
| A Phase 2 Study of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma Latanoprost-PPDS - Glaucoma, Ocular Hypertension | Phase 2 | Withdrawn | Mati Therapeutics Inc. | 2009-03-01 | 2013-09-17 | |
| A Multi-Dose Study With a Treatment for Open-Angle Glaucoma Anecortave Acetate, Placebo - Open-Angle Glaucoma | Phase 2 / Phase 3 | Withdrawn | Alcon Research | 2008-05-01 | 2012-05-30 | |
| Lucentis for New Onset Neovascular Glaucoma Ranibizumab (Lucentis) - Glaucoma, New Onset Glaucoma | Phase 1 / Phase 2 | Withdrawn | University of Illinois at Chicago | 2008-01-04 | 2020-02-17 | |
| Corneal Versus Conjunctival Delivery Using a Delivery Device Xalatan - Glaucoma, Open-Angle, Ocular Hypertension | Phase 2 | Withdrawn | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2021-02-02 |
Glaucoma, Open-Angle (2) · Ocular Hypertension (2) · Carotid Stenosis (1) · Epilepsy (1) · Glaucoma, Neovascular (1) · Port-Wine Stain (1) · Retinal Vein Occlusion (1) · Sturge-Weber Syndrome (1)
Eye Diseases (5) · Ocular Hypertension (3) · Brain Diseases (2) · Cardiovascular Diseases (2) · Central Nervous System Diseases (2) · Nervous System Diseases (2) · Vascular Diseases (2) · Angiomatosis (1) · Arterial Occlusive Diseases (1) · Carotid Artery Diseases (1) · Cerebrovascular Disorders (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Embolism and Thrombosis (1)
Everolimus (1) · Latanoprost (1) · Ranibizumab (1) · anecortave acetate (1)
Alcon Research (1) · Baylor College of Medicine (1) · Mati Therapeutics Inc. (1) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1) · University of Illinois at Chicago (1)
United States (1)
Angus A Wilfong, MD (1) · Michael P Blair, MD (1) · Oscar Cuzzani, MD (1)